having the time Thanks, Danielle. Welcome voice in Good the teacher, my strong one-year the the just to quarter been and time I are earnings Latin grade you're the that's made team has clinical operational, of I of remember year. over fun. back and manufacturing, formed morning, seventh our the for when flies. a anniversary hit past rebuild everyone. call. And second foundation joining to Apologies and XXXX team. Alaunos approach flies I'm Rossi, dedicated so I tempus company, by The progress and fugit, here, my eighth phrase, Mr. proud frog
to Library with Phase X/X level I'm board. our very this as expand future to to manufacturing are same clinical working the and to pleased our say actively TCR-T At capacity expansion, lead dose we're investigators effort. welcome safety enroll, of we're Our President that ahead after and pleased to Operations, second continuing time, moving support Technical to at Vice the consulting trial review Abhi, is and
team expand the together and to training offers. and excited I on just at to the wanted as will but it seek we and to You optimize manufacturing our the worked Small world couple minutes, him Abhi that are Abhi hear beneficiaries of NCI, in both have from of that world-class very say capabilities. a Drew we're
bile in successful with mind collaboration, right Rosenberg the cancer into targeting using for XXXX, cancer Library extend and across TCR-T partnership mutations indications; lung, endometrium, it's tumors. our non-small our team X/X R&D platform. a privileged ovary, X/X cell with patients to and working the to duct most we proof Rosenberg's tumor very continuing combined trial an NCI long-term TCR-T provide importantly reminder, our of expertise, therapies cell we the This Phase improve team, novel on the as different generating pancreas, to efforts, this develop In hotspot and solid our Alaunos have with trial, in Library with a quarter, lives six believe we TCR-T we concept the to look CRADA Phase approach. Dr. basket right And right are and my in approach, our personalized colorectal, of the to When that the Alaunos personalized cancers. solid forward and Dr. be update trial,
down enrolling EGFR. Cancer which based consists street, of Center, that currently XX one of TPXX, cancers these with mutation Anderson library, HLA MD in one patients are pairings we available We the five matching on at our are KRAS, and have four six TCR-T TCRs;
patient recall, dosed billion patient non-small with the targeting cells this trial, own May, first treated may level manufactured KRAS lung five This you dose approximately cell announced the in and our mutation. TCR-T very cGMP a or GXXD that was we cells. patient X we in-house the driver As at facility. has mutation, in TCR-T in The
TCRs institutions. Medicine, dose even approach mutations an two medical of in Cancer look leading was quarter data in published England meeting more the TCR-T let TPXX confidence with were recent papers forward go Anderson, in have treated safety TCR-T be our we the by into XX findings in well clinical to level MD Research. investigators early Journal of using moving second our TCR-T using with our in highlight but One approximately mutations and that look a cells in target these ahead detail in progress greater instilling with discussion Immunology with as to to New by case we that believe academic and cells. KRAS the at the third data the library. published of we're studies in very resulted right the about papers, other remain like at as we're billion of I'd durable the cells hotspot to the at Following responses on year. these We pleased providing review Drew encouraged And but a this trial, and I'll patients track, of
we in Now, have more we're a we better believe and Beauty and approach clinical cost-effective testing that commercially scalable TCRs trial. Sleeping proprietary our these technology, using actively our
to a prepared, capabilities. as like strategy the on working diligently execute manufacturing scout old to Now, motto, be expand multi-pronged to our much we're
long-term sufficient our membrane-bound R&D at expansion in pipeline. this expand IL-XX, we have our we effort while for capacity Now, future to the believe will as next and continue our with least year, us X/X well the study we Phase support clinical serve
our will implementing SOPs products. cGMP we're of First, that work our suite. new for And includes further multiple also this manufacturing process cryopreserved optimize products simultaneous in to production by cell allow introducing
lastly, continuing additional built will capability. increased the support GMP need footprint already expanding And having to hire cGMP are to one suite, we arises. as manufacturing staff we Secondly, successfully investigate physically our
darinaparsin, turn worldwide Pharma. XXXX, formed as over our Darvias. to and known briefly to I touch granted an R&D Solasia upon exclusive that license was call way collaboration have collaboration the before Drew highlight with commercialize back initially also efforts, we agreement This in to develop Now, and a Solasia to I wanted
percentage this by sub-license Solasia. As are license of revenue any we sales-based and eligible part of a agreement, generated milestones for cash
Japan. a be manufacturing continue Health, we're commercialization. that has related to excited refractory And will Now, XXXX, Solasia June In peripheral and in been for them. for of Darvias responsible significant all and the relapsed Welfare, represents to at T-cell lymphoma Solasia Labor, of this costs for their approved team by announced or as for milestone Solasia Ministry
we expand to own these but going development not further for support our will receive Now, internal to now over program. royalties on call the the with were I'm the hand help to academic NCI, sales, Rosenberg to that non-dilutive continued significant papers and to additional capital recently Drew certainly those published. do expect highlight supportive capital on Dr. and the Drew? our partnership also
